At What Age Should a Woman Stop Taking Hormone Replacement?

There is no universal age at which a woman should stop taking hormone replacement therapy (HRT). Medical guidelines once drew a hard line at age 65, but that recommendation has shifted. In 2022, The Menopause Society updated its position to say that the decision to continue HRT beyond 65 should be individualized, factoring in each woman’s symptoms, health risks, and the type of therapy she uses. The real question is less about a number on a calendar and more about the balance of benefits and risks for you specifically, and that balance depends on things like how you take your hormones, how long you have been on them, and what your personal health profile looks like.

Why the “Stop at 65” Rule Changed

For decades, the conventional wisdom was straightforward: menopausal symptoms rarely persist past 65, so HRT beyond that age was unnecessary. That thinking was reinforced by the early results of the Women’s Health Initiative (WHI) trial in the early 2000s, which highlighted risks of breast cancer and cardiovascular events in older women taking combination estrogen-progestin therapy. The media coverage was intense, and research found that every woman in one survey had heard about the WHI results, with more than half reporting it had changed how they used HRT.¹

But the picture turned out to be more complicated. A growing body of evidence showed that vasomotor symptoms like hot flashes do persist in many women well past 65. The blanket age cutoff did not account for how much quality of life those women were sacrificing. The Menopause Society’s updated position now highlights that women over 65 who still benefit from HRT can continue, particularly if they use lower doses and non-oral preparations to minimize risk.²

When You Started Matters More Than When You Stop

One of the most important findings in recent HRT research is the “timing hypothesis.” The cardiovascular effects of hormone therapy depend heavily on when a woman begins treatment relative to menopause. Women who start HRT within ten years of menopause, or before age 60, tend to see reduced rates of cardiovascular events and lower all-cause mortality. Women who start much later may not get those benefits and could face increased cardiovascular risk.³ This timing effect is so strong that some researchers argue it matters more than the total duration of use.⁴

This has practical implications for stopping. A woman who started HRT in her early 50s and is now 62 is in a different position from someone who first began therapy at 63. For the former, the years of use have likely been protective. For the latter, the risk-benefit math may look quite different. A systematic review of studies specifically looking at women who started HRT at 60 or older, or more than ten years after menopause, found no significant increase in cardiovascular risk with estrogen-only therapy or low-dose combined therapy, though higher doses and certain formulations like tibolone did raise stroke risk.⁵

Breast Cancer Risk and Duration of Use

Breast cancer risk is the concern that weighs most heavily in the decision to continue or stop HRT, and the answer depends significantly on the type of therapy. Combined estrogen-progestin therapy carries a meaningfully higher breast cancer risk than estrogen alone, and that risk climbs with longer use. One large study found that women using combined therapy for five or more years had roughly a 50% increase in the most common type of breast cancer and a threefold-plus increase in lobular breast cancer.⁶

Estrogen-only therapy tells a very different story. In the same study, women who took estrogen alone had no significant increase in breast cancer risk regardless of how long they used it, even after 25 years.⁶ This is a crucial distinction that gets lost in broad warnings about HRT and cancer. Women who have had a hysterectomy and take estrogen alone face a fundamentally different risk landscape than women who need the added progestin to protect their uterus. If you have a uterus and are weighing whether to continue combined therapy past five years, breast cancer risk is one of the stronger reasons to reassess.

How You Take It Changes the Clot Risk

Blood clots are another risk that shapes the stopping decision, but here the method of delivery makes a dramatic difference. Oral estrogen, which passes through the liver, carries a substantially higher risk of venous blood clots compared with patches, gels, and sprays that deliver estrogen through the skin. A meta-analysis found that oral estrogen was associated with roughly 60% higher risk of a first blood clot compared with transdermal estrogen.⁷ An earlier case-control study put the contrast even more starkly: oral estrogen users had about 3.5 times the clot risk of non-users, while transdermal estrogen users showed no increased risk at all compared to non-users.⁸

Since clot risk rises with age regardless of HRT, this distinction matters more the older you get. A 55-year-old on oral estrogen may have a fairly low absolute clot risk despite the relative increase. A 68-year-old on the same formulation has a higher baseline risk being amplified. Switching from a pill to a patch is one of the strategies that lets women continue HRT longer while keeping clot risk low. It is part of why current guidelines emphasize non-oral routes for older women who choose to continue therapy.

What Happens to Your Bones When You Stop

Estrogen is one of the most effective protectors against bone loss, and stopping HRT triggers a period of accelerated bone loss that mirrors what happens right after menopause. Research shows that within the first two years of stopping, women lose vertebral bone at roughly the same rate as untreated women lose it in the first two years after menopause.⁹ That accelerated loss then tapers off, and women who used HRT retain a net bone-density advantage even years later. But the initial drop can be alarming and clinically meaningful for women already at risk of fractures.

The longer you use HRT, the more bone protection you accumulate. A 15-year follow-up of Finnish women found that those who used HRT for ten years maintained their spinal bone density essentially unchanged, while non-users lost nearly 5%. Women who used HRT for the full 15 years actually gained bone density. In terms of fractures, ten years of use cut wrist fracture risk by about a third, and 15 years of use cut it by nearly two-thirds.¹⁰ Short-term use of less than five years did not show lasting bone benefits in that study.

A large nested case-control study using UK health data found that current HRT use reduced overall fracture risk by about 25%, but this protection faded in the years after stopping. Interestingly, women who had stopped more than ten years earlier still showed a small residual protective effect compared with women who had never used HRT.¹¹ For women with osteoporosis or high fracture risk, stopping HRT without transitioning to another bone-protective medication deserves careful thought.

Symptom Rebound After Stopping

One of the most common reasons women restart HRT after attempting to stop is the return of hot flashes and other vasomotor symptoms. Among women who tried to discontinue, about three in four experienced hot flashes afterward.¹² Data from the WHI showed that even women who had no moderate or severe symptoms before being assigned to estrogen were more than five times as likely to report hot flashes after stopping compared with those who had been on placebo.¹³ In other words, stopping HRT can unmask symptoms that the therapy had been suppressing, even in women who thought they no longer needed it.

The quality-of-life effects go beyond hot flashes. A 10-year follow-up study of women on continuous combined HRT found that scores on measures of depressed mood, anxiety, sexual interest, and daily functioning improved during therapy and deteriorated in women who stopped.¹⁴ These non-vasomotor effects of withdrawal are often underappreciated.

Tapering Versus Stopping Cold Turkey

A common assumption is that gradually tapering off HRT will ease the transition and reduce rebound symptoms. The evidence does not support this. A randomized controlled trial comparing gradual taper-down with abrupt discontinuation found no difference in the number or severity of hot flashes, quality of life, or the rate at which women went back on HRT during 12 months of follow-up.¹⁵ If you and your doctor decide it is time to stop, you can choose either approach without worrying that one will be significantly harder than the other. That said, this is one of those areas where individual variation is large and the trial evidence is limited, so some clinicians still offer tapering as an option for patient comfort.

Vaginal Estrogen Is a Different Conversation

Low-dose vaginal estrogen for genitourinary symptoms, like vaginal dryness, painful sex, and urinary issues, is not the same as systemic HRT and does not follow the same risk calculus. Vaginal estrogen delivers very low levels of hormone locally with minimal absorption into the bloodstream. Both the North American Menopause Society and the American College of Obstetricians and Gynecologists state that low-dose vaginal estrogen can be used indefinitely if needed, and that it does not require the addition of progestin to protect the uterine lining.¹⁶

This matters because genitourinary symptoms, unlike hot flashes, tend to get worse over time without treatment rather than resolving on their own. Many women who stop systemic HRT for valid reasons continue or start vaginal estrogen separately. If your main reason for staying on hormones is discomfort in the vaginal and urinary area, the stopping question may not apply to you at all.

Early Menopause Changes the Equation Entirely

Women who go through menopause before age 40 (primary ovarian insufficiency) or before 45 (early menopause) face a distinct set of rules. For these women, HRT is not optional supplementation but closer to physiological replacement of hormones their bodies would normally still be producing. Current recommendations advise continuing HRT at least until the average age of natural menopause, around 50, to reduce the increased risks of osteoporosis, cardiovascular disease, and other conditions associated with premature estrogen loss.¹⁷ For these women, stopping HRT at a younger age based on general population guidelines would actually increase their health risks.

What the Long-Term Mortality Data Actually Shows

One question that shapes the stopping decision is whether HRT use over many years helps or hurts survival overall, after all the individual risks and benefits are netted out. The 18-year follow-up of the WHI trials found no significant difference in all-cause mortality between women who had been assigned to hormone therapy and those on placebo. About 27% of women in each group had died, and the overall hazard ratio was essentially neutral at 0.99.¹⁸

A large Danish registry study looking at real-world HRT use found a small mortality benefit: women who had ever used HRT had about a 4% lower adjusted risk of death. The benefit was greatest for women who used HRT for three to ten years, with the adjusted risk roughly 10-11% lower. But at very short durations (less than a year) or very long durations (ten years or more), the benefit was not statistically significant.¹⁹ The practical takeaway is reassuring: moderate-duration HRT use does not appear to shorten life, and may modestly extend it.

What to Do After Stopping

If you do stop HRT and symptoms return, there are non-hormonal options, though none works as well as estrogen. A meta-analysis found that SSRIs and SNRIs (antidepressants commonly prescribed off-label) reduced daily hot flashes by about one per day more than placebo, and gabapentin (a nerve-pain medication) reduced them by about two per day. Clonidine, a blood-pressure drug, also showed a modest effect. Herbal remedies like red clover extract showed no consistent benefit.²⁰ These medications can help women who cannot or choose not to take estrogen, but the researchers noted they are “not optimal choices for most women” and are best suited for those who are highly symptomatic and have no estrogen option.

Beyond symptom management, the metabolic effects of stopping HRT are worth addressing. Discontinuing hormone therapy tends to raise total cholesterol and LDL cholesterol. One study found that women who stopped HRT and made no lifestyle changes saw their total cholesterol jump by an average of more than 22 mg/dL, while women who adopted a structured lifestyle intervention (diet and exercise changes) experienced essentially no cholesterol increase after stopping.²¹ If you are planning to stop HRT, actively working on cardiovascular fitness and diet around the same time can blunt the metabolic rebound.

The Brain and Dementia Risk

The relationship between HRT and dementia is one of the most uncertain and contentious areas in this field. The timing hypothesis applies here too: estrogen therapy started within the first five years of menopause may help protect against cognitive decline, while therapy started much later does not and might even be harmful.²² A large UK study using primary care data found that estrogen-only therapy used for ten or more years was associated with a modest decrease in overall dementia risk, but combined estrogen-progestin therapy used for the same duration was associated with a roughly 19% increase in Alzheimer’s disease risk.²³

Genetic background may further complicate the picture. Carriers of the APOE4 gene variant, which is the strongest genetic risk factor for Alzheimer’s, appear to respond differently to HRT. Research suggests that APOE genotype can modify how estrogen therapy affects cognitive decline, dementia risk, and even non-brain outcomes like bone loss and cholesterol changes after menopause.²⁴ The science here is still evolving, and no guidelines yet recommend routine genetic testing to guide HRT decisions. But it hints at a future where the stopping question might be partly answered by a blood test.

Personalized Risk Assessment in Practice

Given all of these moving parts, the practical path forward involves periodic reassessment rather than a single predetermined stop date. Most guidelines recommend that women and their clinicians review HRT annually, weighing the ongoing symptom burden against the evolving risk profile. A woman of 58 who is still having disruptive hot flashes and is on transdermal estrogen at a low dose is in a very different position from a 58-year-old with no remaining symptoms who is taking oral combined therapy. The formulation, the dose, the route of delivery, the woman’s body-mass index, her family history of breast cancer or blood clots, and whether she has had a hysterectomy all feed into the calculation.²⁵

A few factors tilt the scale toward continuing: persistent symptoms that meaningfully affect quality of life, high fracture risk without an alternative bone-protective plan, use of transdermal rather than oral estrogen, and use of estrogen alone rather than combined therapy. A few tilt it toward stopping: a personal or strong family history of breast cancer, a history of blood clots, use of oral rather than transdermal formulations at higher doses, and the absence of symptoms that still require treatment. Neither list is a checklist that produces a yes-or-no answer. It is a framework for the conversation you should be having with your doctor regularly, not just once.